Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Goodwill Amortizatization of Intangibles Asset Writedowns and Impairment Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Cash from Restructuring Change in Account Payables Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Receivables Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation and Depletion Dividends Paid - Common Exchange Rate Effect Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Income Non-cash Items Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Altimmune (ALT) Long-Term Debt Issuances (2017)

Historic Long-Term Debt Issuances for Altimmune (ALT) over the last 2 years, with Q1 2017 value amounting to $3.0 million.

Altimmune's Long-Term Debt Issuances changed N/A to $3.0 million in Q1 2017 from the same period last year, while for Dec 2017 it was $3.0 million, marking a year-over-year increase of 2075.12%. This contributed to the annual value of $632000.0 for FY2020, which is N/A changed from last year.
Altimmune's Long-Term Debt Issuances amounted to $3.0 million in Q1 2017.
In the past 5 years, Altimmune's Long-Term Debt Issuances ranged from a high of $3.0 million in Q1 2017 and a low of $3.0 million during Q1 2017